The Muscle Wasting Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Muscle Wasting Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Muscle Wasting Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Muscle Wasting Disorders and features dormant and discontinued products.
GlobalData tracks 32 drugs in development for Muscle Wasting Disorders by 28 companies/universities/institutes. The top development phase for Muscle Wasting Disorders is preclinical with 16 drugs in that stage. The Muscle Wasting Disorders pipeline has 27 drugs in development by companies and five by universities/ institutes. Some of the companies in the Muscle Wasting Disorders pipeline products market are: Novo Nordisk, Aventi and Epitracker.
The key targets in the Muscle Wasting Disorders pipeline products market include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR), and Cannabinoid Receptor 2 (CB2 or CX5 or CNR2).
See Also:
The key mechanisms of action in the Muscle Wasting Disorders pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with four drugs in Preclinical. The Muscle Wasting Disorders pipeline products include seven routes of administration with the top ROA being Oral and ten key molecule types in the Muscle Wasting Disorders pipeline products market including Small Molecule, and Fusion Protein.
Muscle Wasting Disorders overview
Muscle wasting is evident in diverse pathologies like cancer, chronic kidney disease, heart failure, chronic obstructive pulmonary disease (COPD), and during aging or extended inactivity. Diminished muscle mass and function correlate with increased morbidity and mortality, along with a diminished quality of life. Elevated levels of pro-inflammatory cytokines are frequently observed in the plasma of individuals experiencing muscle wasting conditions, prompting interest in anti-inflammatory drugs as potential treatments. However, the effectiveness of such interventions remains variable and contingent on the specific context of the underlying pathology.
For a complete picture of Muscle Wasting Disorders’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
